Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PROPHYLACTIC AND THERAPEUTIC AGENT FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
Document Type and Number:
WIPO Patent Application WO/2015/098591
Kind Code:
A1
Abstract:
1-(Benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof is already known to exhibit an excellent activity/effect as an anti-depression drug, a psychotropic drug, an anti-Parkinson's disease drug and an anti-Alzheimer's disease drug. However, it is truly unknown that the compound is effective for the prevention or treatment of attention-deficit/hyperactivity disorder (ADHD). The present invention newly finds that the 1-(benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof is effective for the prevention or treatment of ADHD. As a result, the present invention has been accomplished.

Inventors:
TOGASHI HIROKO (JP)
HIRADE SACHIKO (JP)
YONEDA FUMIO (JP)
TAKAHATA KAZUE (JP)
Application Number:
JP2014/083100
Publication Date:
July 02, 2015
Filing Date:
December 15, 2014
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
FUJIMOTO CO LTD (JP)
International Classes:
A61K31/343; A61K31/135; A61K31/137; A61K31/155; A61K31/165; A61K31/4168; A61K31/4458; A61K45/00; A61P25/00
Domestic Patent References:
WO2000026204A12000-05-11
WO1999007667A11999-02-18
WO1999007667A11999-02-18
WO2000026204A12000-05-11
WO2006057211A12006-06-01
WO2001007704A12001-02-01
WO2007001015A12007-01-04
Foreign References:
JP2003089643A2003-03-28
JP2013056944A2013-03-28
Other References:
SEIICHIRO SHIMAZU ET AL.: "Transporter- mediated actions of R-(-)-1-(benzofuran-2-yl)- 2-propylaminopentane", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 482, 2003, pages 9 - 16, XP055355385
FUMIO YONEDA ET AL.: "Structure-activity studies leading to (-)1-(Benzofuran-2-yl)-2- propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of Catecholamines and Serotonin in the brain", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 9, 2001, pages 1197 - 1212, XP055355387
TIMOTHY E. WILENS: "Mechanism of Action of Agents Used in Attention-Deficit/Hyperactivity Disorder", J CLIN PSYCHIATRY, vol. 67, no. SUPPL, 2006, pages 32 - 37, XP008184070
See also references of EP 3087984A4
"The Diagnostic and Statistical Manual of Mental Disorders", AMERICAN PSYCHIATRIC ASSOCIATION, article "Text Revision (DSM-IV-TR"
SWANSON JM ET AL., NEUROPSYCHOLOGY REVIEW, vol. 17, 2007, pages 39 - 59
FRANKE B ET AL., HUMAN GENETICS, vol. 126, 2009, pages 13 - 50
"Diagnosis/Therapy Guideline of Attention-Deficit/Hyperactivity Disorder (ADHD", 2008, JIHO, INC.
SHIMAZU S ET AL., LIFE SCIENCE, vol. 72, 2003, pages 2785 - 92
JAPANESE JOURNAL OF PHARMACOLOGY, vol. 82, no. 1, 2000, pages 230P
JAPANESE JOURNAL OF PHARMACOLOGY, vol. 85, no. 1, 2001, pages 249P
NEUROPSYCHOPHARMACOLOGY, vol. 27, 2002, pages 699 - 711
SARTER ET AL., PSYCHOPHARMACOLOGY (BERL, vol. 94, 1988, pages 491 - 5
Attorney, Agent or Firm:
TANI, YOSHITAKA (JP)
Valley Yoshitaka (JP)
Download PDF: